Verona Pharma plc (VRNA)

Verona Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	42.26	-	-	40	-
Other Revenue	0.02	-	0.46	-	-
Revenue	42.28	-	0.46	40	-
Revenue Growth (YoY)	-	-	-98.86%	-	-
Cost of Revenue	2.58	-	0.35	-	-
Gross Profit	39.7	-	0.11	40	-
Selling, General & Admin	149.75	50.35	26.58	33.91	29.77
Research & Development	40.97	16.11	39.65	63.78	36.24
Operating Expenses	190.72	66.47	66.23	97.68	66.01
Operating Income	-151.03	-66.47	-66.12	-57.68	-66.01
Interest Expense	-23.54	-2.06	-0.52	-0.34	-0.04
Interest & Investment Income	15.26	12.76	2.82	0.01	0.12
Currency Exchange Gain (Loss)	-0.17	1.87	-3.82	0.18	2.06
Other Non Operating Income (Expenses)	-	-	-	2.25	-1.14
EBT Excluding Unusual Items	-159.48	-53.9	-67.63	-55.59	-65
Other Unusual Items	-3.65	-	-0.82	-	-
Pretax Income	-163.13	-53.9	-68.45	-55.59	-65
Income Tax Expense	10.29	0.47	0.25	-0.02	0.15
Net Income	-173.42	-54.37	-68.7	-55.57	-65.15
Net Income to Common	-173.42	-54.37	-68.7	-55.57	-65.15
Shares Outstanding (Basic)	82	79	66	59	33
Shares Outstanding (Diluted)	82	79	66	59	33
Shares Change (YoY)	2.86%	19.86%	11.81%	79.97%	149.64%
EPS (Basic)	-2.13	-0.69	-1.04	-0.94	-1.98
EPS (Diluted)	-2.16	-0.72	-1.04	-0.94	-1.98
Free Cash Flow	-122.78	-50.22	-59.89	-33.27	-45.16
Free Cash Flow Per Share	-1.51	-0.63	-0.91	-0.56	-1.37
Gross Margin	93.89%	-	24.45%	100.00%	-
Operating Margin	-357.22%	-	-14435.81%	-144.21%	-
Profit Margin	-410.18%	-	-15000.22%	-138.92%	-
Free Cash Flow Margin	-290.41%	-	-13076.64%	-83.17%	-
EBITDA	-149.97	-65.79	-65.48	-57.05	-65.39
EBITDA Margin	-	-	-	-142.63%	-
D&A For EBITDA	1.06	0.68	0.64	0.63	0.62
EBIT	-151.03	-66.47	-66.12	-57.68	-66.01
EBIT Margin	-	-	-	-144.21%	-
Revenue as Reported	42.28	-	0.46	-	-

Updated Apr 29, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q